Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Praxis Precision Medicines and keeping the price target at $105.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Douglas Tsao has given his Buy rating due to a combination of factors that highlight the promising potential of Praxis Precision Medicines. The RADIANT study’s efficacy data surpassed expectations, showing significant seizure reduction and a noteworthy responder rate, which suggests that the treatment could lead to seizure freedom over time. The data indicates that vormatrigine, a key compound in their pipeline, has the potential to match or exceed the efficacy of existing treatments like cenobamate, without the associated drug-drug interaction issues.
Additionally, the safety profile of vormatrigine appears favorable compared to other anti-seizure medications, with no instances of cutaneous hypersensitivity or falls reported. Although the discontinuation rate was higher than anticipated, it is believed that this could improve as physicians gain more experience with the drug. The ongoing POWER studies are expected to further validate these findings and potentially enhance the drug’s efficacy and safety profile, making it a strong candidate for widespread adoption in the treatment of focal onset seizures.
In another report released today, Needham also maintained a Buy rating on the stock with a $80.00 price target.